ArticlePediatric rheumatology online journal2018
Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy.
Article in Pediatric rheumatology online journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Pooled it
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.The Cochrane database of systematic reviews · 2022Pooled it
- Juvenile idiopathic arthritis-associated uveitis outcomes at an Australian tertiary paediatric hospital.Clinical rheumatology · 2026Article
- Systemic immunosuppressive therapy in juvenile idiopathic arthritis-associated uveitis.International ophthalmology · 2026Article
- Gut microbiota and uveitis: exploring novel mechanisms of inflammatory ocular diseases via the gut-eye axis.Frontiers in microbiology · 2026Review
- Features of patients with uveitis associated with juvenile idiopathic arthritis required eye surgery.World journal of clinical pediatrics · 2025Article
- Treatment outcomes of a Swiss non-infectious paediatric uveitis cohort: retrospective study over ten years.Journal of ophthalmic inflammation and infection · 2025Article
- Ocular complications in pediatric non-infectious anterior uveitis in long-term follow-up: population-based cohort study.Journal of ophthalmic inflammation and infection · 2025Article
- Minor salivary gland biopsy in the diagnosis of definite ocular sarcoidosis in paediatric granulomatous uveitis.Pediatric rheumatology online journal · 2025Article
- The management of adult and paediatric uveitis for rheumatologists.Nature reviews. Rheumatology · 2024Review
- Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy.Eye (London, England) · 2024Article
- Uveitis Profile in Children and Its Impact on Vision at Queen Rania Children's Hospital.Cureus · 2024Article
- Laser Flare Photometry to Monitor Childhood Chronic Uveitis: A Preliminary Report of a Monocentric Italian Experience.Diagnostics (Basel, Switzerland) · 2023Article
- Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report.Pediatric rheumatology online journal · 2023Article
- Encouraging visual outcomes in children with idiopathic and JIA associated uveitis: a population-based study.Pediatric rheumatology online journal · 2023Article
- Paediatric anterior uveitis management in the USA: a single-centre, 10-year retrospective chart review exploring the efficacy and safety of systemic immunomodulatory therapy.Eye (London, England) · 2023Article
- Improved clinical outcomes in patients with juvenile idiopathic arthritis associated uveitis in the last decade.Acta ophthalmologica · 2022Article
- Comprehensive Assessment of Quality of Life, Functioning, and Mental Health in Children With Juvenile Idiopathic Arthritis and Noninfectious Uveitis.Arthritis care & research · 2022Article
- A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis.Translational vision science & technology · 2022Article
- Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience.Frontiers in pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a paucity of data on the ocular outcomes in paediatric non-infectious uveitis since the introduction of the biologic agents. The purpose of this study was to outline the clinical characteristics of children with non-infectious uveitis and determine the visual outcomes and ocular complication rates in the modern era.
methodsChildren with non-infectious uveitis from January 2011 to December 2015 were identified. Data was collected at baseline, 1, 3, 5, and 10 years post diagnosis. The incidence rates of visual impairment, structural ocular complications and surgical intervention were calculated. Using logistic regression the association between various baseline characteristics and later visual impairment was investigated.
resultsOf the 166 children, 60.2% (n = 100) had a systemic disease association. 72.9% (n = 121) children received methotrexate, 58 children progressed to a biologic. The incidence rates of visual acuity loss to > 0.3 LogMAR (6/12) and to ≥1.0 LogMAR (6/60) were 0.05/Eye Year (EY) and 0.01/EY, respectively. Visual outcomes in the Juvenile Idiopathic Arthritis associated Uveitis (JIA-U) and Idiopathic Uveitis cohorts were not statistically significant. Of the 293 affected eyes, posterior synechiae was the predominant complication on presentation, while cataract had the highest incidence rate (0.05/EY). On direct comparison, children with JIA-U were statistically significantly more likely to develop glaucoma while children with Idiopathic Uveitis were statistically significantly more likely to develop macular oedema.
conclusionOne third of children received a biological therapy, reflecting increasing utilisation and importance of biological agents in the management of inflammatory conditions. Rates of visual impairment and ocular complications are an improvement on previously published data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.